- Poster presentation
- Open Access
Enhancing anti-tumor immunity through local gene delivery to lymph nodes
© Dold and Jewell 2015
- Published: 4 November 2015
- Vaccine Component
- Dendritic Cell Activation
- Murine Splenocytes
- Assess Gene Expression
- Therapeutic Cancer Vaccine
Biodegradable polymer carriers offer attractive features for therapeutic cancer vaccines including delivery of multiple vaccine components, efficient internalization, and sustained release of adjuvants and tumor-associated antigens (TAAs). We previously demonstrated that local delivery of depots containing nucleic acid-based toll-liked receptor agonists (TLRas) to lymph nodes (LNs) potently enhances antigen-specific T cell immunity. Building on this work, we hypothesized that local LN delivery of microparticles loaded with TAA-encoding plasmid DNA (pDNA) and TLRas might drive strong local expression and presentation of antigen by LN-resident antigen presenting cells. These effects could help drive more potent and effective CD8+ T cell functions that slow or stop tumor growth.
Plasmids were designed and synthesized to encode model reporter genes or a conserved T cell peptide epitope, TRP2 (SVYDFFVWL) for human and murine melanoma. Screening studies with primary dendritic cells utilized poly(lactic-co-glycolide) microparticles synthesized by water-oil-water emulsion, stabilized with polyvinyl alcohol. The inner aqueous phase was loaded with a TLR9 agonist (CpG oligodeoxynucleotide) and pDNA. Size and loading were characterized by laser diffraction and UV-vis spectroscopy. Murine splenocytes expressing CD11c were harvested, isolated, and treated overnight in triplicate with empty particles or particles encapsulating CpG only, pDNA only, or both CpG+pDNA. Cells were analyzed by flow cytometry using markers for viability (DAPI-) and dendritic cell activation (CD40+, CD80+, CD86+).
The pDNA vector for the TRP2 epitope was designed to express degradable peptide spacers (AAY) flanking repeating units of the antigenic epitope. This vector was synthesized with and without a sequence encoding ubiquitin to provide efficient proteasomal peptide processing and antigen expression. Particles exhibited mean diameters 2.5-4.4µm depending on cargo and synthesis energy. Cargo loading was measured for CpG particles at 3.8µg CpG/mg particles and for pDNA particles at 11.1µg pDNA/mg particles. During ex vivo screening, particles containing cargo increased CD40, CD80, and CD86 expression compared to empty particles and did not impact cell viability compared to controls treated with soluble TLRas.
Initial studies demonstrate microparticles loaded with TLRa and pDNA effectively stimulate primary immune cells, supporting a platform for loading and driving local TAA expression alongside vaccine components like TLRas. Ongoing studies will assess gene expression levels in primary cells and secondary lymph organs using a mouse melanoma model and will correlate local TAA expression with antigen-specific T cell expansion and efficacy during tumor challenge.
This work was supported in part by Alliance for Cancer Gene Therapy Grant #15051543.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.